Top

Published in:

01-08-1998 | ORIGINAL ARTICLE

Effect of carboplatin on response and palliation in hormone-refractory prostate cancer

Authors: W. F. Jungi, Jürg Bernhard, Christoph Hürny, Shu-Fang Hsu Schmitz, Silvia Hanselmann, Heidi Gusset, Dietegen Pestalozzi, Aron Goldhirsch, for the Swiss Group for Clinical Cancer Research (SAKK)

Published in: Supportive Care in Cancer | Issue 5/1998

Title: Effect of carboplatin on response and palliation in hormone-refractory prostate cancer
Authors: W. F. Jungi
Jürg Bernhard
Christoph Hürny
Shu-Fang Hsu Schmitz
Silvia Hanselmann
Heidi Gusset
Dietegen Pestalozzi
Aron Goldhirsch
for the Swiss Group for Clinical Cancer Research (SAKK)
Publication date: 01-08-1998
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 5/1998
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s005200050195

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 5/1998

Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement?

Empiric therapy for the febrile neutropenic patient

Stratification in clinical trials of febrile neutropenia

Methodology for clinical trials in cancer patients with febrile neutropenia

Competent gastrostomy for patients with head and neck cancer

Palliative care in Italy: the current situation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer